Potential Influence of <i>ADAM9</i> Genetic Variants and Expression Levels on the <i>EGFR</i> Mutation Status and Disease Progression in Patients with Lung Adenocarcinoma.

ABSTRACT: Lung adenocarcinoma (LUAD) is driven by epidermal growth factor receptor (EGFR) mutations, making it a key therapeutic target. ADAM9, a member of the A disintegrin and metalloproteinase (ADAM) family, facilitates the release of growth factors and was implicated in activating the EGFR-mediated progression in several cancer types. In this study, we explored potential associations among ADAM9 single-nucleotide polymorphisms (SNPs), the EGFR mutation status, and the clinicopathological progression of LUAD in a Taiwanese population. In total, 535 LUAD patients with various EGFR statuses were enrolled, and allelic distributions of ADAM9 SNPs-located in promoter and intron regions, including rs78451751 (T/C), rs6474526 (T/G), rs7006414 (T/C), and rs10105311 (C/T

SUBMITTER: Chang JH 

PROVIDER: S-EPMC12111331 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature